The Ultimate Guide to Afoxolaner: Everything You Need to Know
Afoxolaner is a revolutionary active pharmaceutical ingredient (API) that has transformed the field of veterinary medicine, particularly in treating parasitic infections in pets.
As an Afoxolaner API importer, medicine manufacturer, or compounding pharmacy, understanding the full potential of Afoxolaner is crucial for staying competitive in the market.
This comprehensive guide will delve into Afoxolaner’s science, applications, and benefits.
Whether you’re looking to source high-quality Afoxolaner API or seeking insights into its mechanisms and efficacy, this blog post is your ultimate resource.
What is Afoxolaner?
Afoxolaner is a systemic insecticide and acaricide belonging to the isoxazoline class, a relatively new category of compounds that have demonstrated exceptional efficacy against ectoparasites.
Chemically known as 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide, this complex molecule features multiple halogen atoms that contribute to its biological activity and stability.
The compound exists as a crystalline solid at room temperature with limited water solubility, necessitating specialized formulation approaches for optimal bioavailability.
Its log P value of approximately 5.9 indicates high lipophilicity, which contributes to its extensive tissue distribution and prolonged duration of action in treated animals.
These physicochemical properties present both challenges and opportunities for formulators seeking to develop effective delivery systems.
From a regulatory perspective, Afoxolaner has been approved in numerous markets under various brand names, most notably as the active ingredient in NexGard® (Merial/Boehringer Ingelheim) for dogs and more recently in combination products for broader spectrum parasite control.
Understanding the regulatory status in target markets is essential for API importers and manufacturers looking to capitalize on this compound’s commercial potential.
What is Afoxolaner used for?
1. Flea Infestation
Afoxolaner is highly effective against fleas, killing them within hours of ingestion.
It eliminates existing fleas and prevents re-infestation by inhibiting their life cycle.
Fleas can cause discomfort and allergic reactions (flea allergy dermatitis) and transmit diseases, including tapeworms, making Afoxolaner a vital tool for parasite control.
2. Tick Infestation
Ticks carry serious diseases, including Lyme disease, ehrlichiosis, and anaplasmosis.
Afoxolaner rapidly eliminates ticks, reducing the risk of tick-borne illnesses in pets.
Its effectiveness against multiple tick species ensures comprehensive protection for dogs and cats.
3. Preventing Parasite Re-Infestation
One of the standout features of Afoxolaner is its ability to provide long-lasting protection.
A single dose can last weeks, offering sustained relief from fleas and ticks.
This makes it a convenient and efficient option for pet owners and veterinarians.
4. Other Ectoparasites
Afoxolaner also targets other ectoparasites, such as mites, although its primary use is for fleas and ticks.
Its broad-spectrum activity makes it a versatile choice for veterinary practitioners.
How Does Afoxolaner Work? (Mechanism of Action)
Afoxolaner belongs to the isoxazoline class of drugs, which act on the nervous system of parasites.
Here’s a step-by-step explanation of its mechanism of action:
Targeting Insect and Acaricidal Receptors:
Afoxolaner selectively binds to insect and acaricidal receptors in the nervous system of fleas and ticks. These receptors regulate sodium channels, which are essential for nerve impulse transmission.Blocking Sodium Channels:
By binding to these receptors, Afoxolaner disrupts the function of sodium channels, preventing the normal flow of sodium ions. This leads to overstimulation of the parasite’s nervous system.Paralysis and Death:
The overstimulation of the nervous system results in paralysis, ultimately leading to the parasite’s death. This rapid action ensures that fleas and ticks are eliminated quickly, reducing the risk of disease transmission.Selective Toxicity:
Afoxolaner is highly selective for flea and tick receptors and does not affect mammals’ nervous systems. This ensures that it is safe for pets, with minimal risk of adverse effects.
What Are Afoxolaner Side Effects?
While Afoxolaner is generally well-tolerated, it is essential to be aware of potential side effects.
Here are the most common side effects:
Mild Side Effects:
- Vomiting
- Diarrhea
- Decreased appetite
- Lethargy
These side effects are typically mild and resolve on their own.
However, if symptoms persist or worsen, veterinary intervention may be necessary.
Rare but Serious Side Effects:
- Neurological symptoms (e.g., ataxia, tremors)
- Severe allergic reactions (e.g., itching, swelling, difficulty breathing)
If these rare side effects occur, immediate veterinary attention is required.
It is also crucial for manufacturers to ensure the highest purity and quality of Afoxolaner API to minimize the risk of adverse effects.
Afoxolaner Dosage and Administration
The dosing regimen for Afoxolaner follows a weight-based protocol that ensures effective parasite control while maintaining safety margins.
For dogs, the recommended dosage range is 2.5 to 7.0 mg/kg body weight, administered orally once monthly.
This flexibility allows veterinarians and pet owners to select appropriate formulations based on the animal’s size, with various tablet strengths available to accommodate different weight ranges.
Administration guidelines recommend giving Afoxolaner with or without food, as absorption is not significantly affected by feeding status.
This administration flexibility enhances owner compliance compared to products that require precise timing relative to meals.
The chewable formulation of many commercial products enhances palatability and ease of administration, particularly in dogs that are difficult to administer conventional tablets to.
For special populations, specific considerations apply. The product is not recommended for puppies under 8 weeks of age or weighing less than 2 kg, as safety and effectiveness have not been established in these groups.
In breeding, pregnant, or lactating dogs, use should be based on veterinary risk assessment, though available data suggest a wide margin of safety.
In cases of severe parasitic infestation, particularly with demodectic mange, extended treatment protocols beyond three monthly doses may be necessary based on clinical response and skin scrapings.
Table: Afoxolaner Dosage Guidelines by Body Weight
| Dog Weight (kg) | Recommended Tablet Strength | Afoxolaner Content |
|---|---|---|
| 2 – 4 kg | 11.3 mg tablet | 11.3 mg |
| 4 – 10 kg | 28.3 mg tablet | 28.3 mg |
| 10 – 25 kg | 68 mg tablet | 68 mg |
| 25 – 50 kg | 136 mg tablet | 136 mg |
| >50 kg | Combination of tablets | Adjusted to weight |
Administration Tips:
- Follow theveterinarian’ss instructions carefully.
- Administer the medication with food to enhance absorption.
- Monitor the pet for any adverse reactions after administration.
For afoxolaner tablet manufacturers, ensuring accurate dosing and quality control is paramount to delivering a safe and effective product.
Afoxolaner Precautions and Drug Interactions
Several vital precautions must be considered when formulating, distributing, or recommending Afoxolaner-containing products.
While the API itself has a wide safety margin, it is essential to follow appropriate use guidelines to minimize risks.
In heartworm-endemic areas, dogs should be tested for existing heartworm infections before starting treatment with combination products containing milbemycin oxime, as this can cause adverse reactions in heartworm-positive animals.
Regarding drug interactions, Afoxolaner itself has a relatively low interaction potential, as cytochrome P450 enzymes do not extensively metabolize it and it does not inhibit major CYP isoforms.
However, in combination products containing milbemycin oxime, essential interactions may occur. Milbemycin is a substrate for P-glycoprotein (P-gp), and concurrent use with other P-gp substrates (such as digoxin, doxorubicin) or macrocyclic lactones may increase toxicity.
Environmental considerations should also be addressed. While Afoxolaner is generally safe for mammals, its potential impacts on non-target organisms, particularly aquatic invertebrates, should be considered during manufacturing and waste disposal.
Appropriate containment measures should be implemented to prevent environmental contamination during the handling and formulation of APIs.
For human safety, standard precautions for handling pharmaceuticals should be followed.
Although the risk is low, accidental ingestion may cause gastrointestinal disturbances, and medical advice should be sought with the product label in hand.
Appropriate personal protective equipment should be used during manufacturing and compounding processes to minimize occupational exposure to hazards.
Afoxolaner vs. Other Medications
Afoxolaner stands out among its competitors for its efficacy, safety, and convenience. Here’s how it compares to other antiparasitic medications:
1. Afoxolaner vs. Fipronil:
- Afoxolaner: Targets both fleas and ticks, with a longer duration of action (up to 30 days).
- Fipronil: Also effective against fleas and ticks but may require more frequent application (every 30 days or as directed).
2. Afoxolaner vs. Imidacloprid:
- Afoxolaner: Offers broader protection against fleas and ticks, with a longer-lasting effect.
- Imidacloprid: Effective against fleas but may not provide adequate protection against ticks.
3. Afoxolaner vs. Fluralaner:
- Afoxolaner: Offers similar efficacy and safety with comparable dosing schedules.
- Fluralaner: Also adequate, but may have a slightly different pharmacokinetic profile.
Fooxolaner’s superior efficacy and versatility make it a preferred choice in the veterinary market.
Is Afoxolaner Safe for Dogs and Cats?
The safety profile of Afoxolaner has been extensively evaluated in both dogs and cats, though regulatory approvals and product formulations differ between species.
In dogs, Afoxolaner has demonstrated an excellent safety profile across multiple breeds, ages, and reproductive statuses when used according to label recommendations.
For canine applications, safety studies have shown that Afoxolaner is well tolerated at multiples of the recommended dose, with no significant adverse effects observed, even at 5 times the maximum recommended dose, across various breeds.
Its safety in breeding, pregnant, and lactating dogs has been established, though veterinary supervision is still recommended in these populations.
Regarding feline safety, while Afoxolaner has shown efficacy against parasites in cats, its use in this species is more limited and often off-label depending on the region.
Cats metabolize drugs differently from dogs, particularly regarding glucuronidation pathways, so specific feline safety data should be consulted before formulating products for this species.
Some commercial products containing Afoxolaner are approved explicitly for cats in specific markets, with demonstrated safety profiles when used according to species-specific recommendations.
Breed-specific considerations are minimal with Afoxolaner compared to some other parasitides.
Unlike ivermectin, which can cause severe neurotoxicity in dogs with MDR1 mutations (common in Collies, Australian Shepherds, and related breeds), Afoxolaner does not appear to be affected by this genetic mutation, making it safe for use in these susceptible breeds.
How Long Does Afoxolaner Take to Work?
The onset of action for Afoxolaner is remarkably rapid, providing quick relief from parasite burdens.
For flea infestations, the compound begins killing parasites within 4-8 hours after administration, with nearly 100% efficacy within 24 hours.
This rapid knockdown effect helps alleviate the discomfort associated with flea bites and reduces environmental contamination with eggs and larvae.
Against tick species, Afoxolaner demonstrates rapid acaricidal activity, preventing attachment and feeding within hours of administration.
This quick action is particularly valuable for reducing the transmission of tick-borne diseases such as Lyme disease, ehrlichiosis, and anaplasmosis, as ticks typically need to feed for several hours before transmitting these pathogens.
The duration of efficacy is equally impressive, maintaining protective plasma concentrations for approximately 30 days after a single dose.
This prolonged activity ensures continuous protection against reinfestation throughout the monthly dosing interval, making it highly effective for preventive care programs.
The extended half-life (~2-3 weeks) contributes to this sustained effect, allowing for some flexibility in dosing schedules without compromising efficacy.
For therapeutic applications such as demodicosis or scabies, clinical improvement is typically observed within the first month of treatment. Still, complete resolution may require multiple monthly doses depending on disease severity.
Regular monitoring through skin scrapings is recommended to determine treatment duration, with therapy continuing until one month after the second negative scraping in demodectic mange cases
Global Sourcing Tips for Afoxolaner API
Sourcing high-quality Active Pharmaceutical Ingredient (API) is a critical concern for manufacturers considering Afoxolaner production.
The global market offers options ranging from the innovator company (Boehringer Ingelheim) to various generic API manufacturers, primarily located in Asia.
When selecting an API supplier, several factors must be carefully evaluated to ensure quality, reliability, and regulatory compliance.
Quality assessment should begin with thorough verification of certificates of analysis (CoA), which should confirm identity, purity (>99%), and appropriate physicochemical characteristics per compendial standards when available.
Although Afoxolaner may not yet have monographs in major pharmacopeias, reputable suppliers should provide comprehensive analytical data demonstrating compliance with their established specifications.
Additionally, suppliers should provide documentation of good manufacturing practice (GMP) compliance and be willing to undergo facility audits when possible.
Supply chain considerations include evaluating the supplier’s track record for reliability, capacity to meet volume requirements, and logistical capabilities for international shipping with appropriate cold chain maintenance when required.
While Afoxolaner is relatively stable at room temperature, protection from light and moisture is essential during transport and storage.
Developing relationships with multiple approved suppliers can help mitigate risks associated with supply disruptions.
For companies importing API into regulated markets, a thorough understanding of import regulations, customs requirements, and necessary documentation is essential for smooth clearance processes.
Pain Points for API Importers, Manufacturers, and Compounding Pharmacies
For API Importers, Manufacturers, and Compounding Pharmacies, sourcing high-quality APIs such as Afoxolaner presents several challenges.
Here’s how we address their pain points:
1. Quality Assurance:
Ensuring the highest purity and potency of Afoxolaner API is non-negotiable.
Our products undergo rigorous testing to meet international pharmacopeial standards.
2. Compliance and Regulations:
We provide comprehensive documentation, including COAs, MSDS, and regulatory certifications, to help manufacturers navigate complex regulatory requirements.
3. Cost-Effectiveness:
We offer competitive pricing without compromising quality, helping manufacturers optimize production costs.
4. Supply Chain Reliability:
Our robust supply chain ensures consistent availability of Afoxolaner API, minimizing production delays and supply shortages.
Conclusion
Afoxolaner is a game-changer in veterinary medicine, offering unparalleled efficacy, safety, and convenience.
For API importers, medicine manufacturers, and compounding pharmacies, leveraging the benefits of Afoxolaner can give you a competitive edge in the market.
By understanding its mechanism of action, applications, and advantages, you can make informed decisions and deliver high-quality products to your customers.
Whether you’re sourcing Afoxolaner API or developing innovative veterinary formulations, our team is here to support you every step of the way.
Are you ready to revolutionize your veterinary product line with Afoxolaner?
Contact us today to learn more about our Afoxolaner API and to tell us how we can help you meet your business needs.
Let’s work together to create safe, effective, and innovative pet solutions worldwide.
Disclaimer:
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
c’est faux, ce sont des canaux chlorure ligand dependant du GABA.
The MOA?